Esperion Theraptc Cm (ESPR) 16.74 $ESPR Looking Into

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 10:08 PM

Esperion Theraptc Cm (ESPR) 16.74 $ESPR

Looking Into Biotech's Crystal Ball
ACCESSWIRE - Thu May 19, 3:35PM CDT
LAS VEGAS, NV / ACCESSWIRE / May 19, 2016 / While biotech investing is riddled with risk it is also ripe with reward. One way we can mitigate risk in this rough and tumble sector that has made millionaires of many and bankrupted some is to pay attention to subtext and follow the company's true progress. Especially when dealing with development stage biotechs.
ESPR: 16.74 (-1.01)

Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 7:05AM CDT
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today provided bempedoic acid (ETC-1002) development program updates and financial results for the first quarter ended March 31, 2016.
ESPR: 16.74 (-1.01)

Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.74 (-1.01), CMRX: 4.14 (-0.44), GERN: 2.77 (-0.04), CYTX: 2.27 (-0.01), CLDX: 4.12 (-0.20), SGMO: 6.44 (-0.31), PTCT: 7.24 (-0.30), ATHX: 2.38 (+0.03), MNKD: 1.01 (-0.02)

IRRAS AB Appoints Anders P. Wiklund to its Board of Directors
PR Newswire Europe - Wed Mar 23, 7:01AM CDT
- Mr. Wiklund is a well recognized and seasoned healthcare executive
ESPR: 16.74 (-1.01)

Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 16.74 (-1.01), VCEL: 2.43 (-0.07), SGMO: 6.44 (-0.31), ZYNE: 8.77 (-0.28)

INVESTOR DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc.
BusinessWire - Fri Mar 11, 8:35PM CST
Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) for potential violations of federal securities laws and breaches of the Esperion Board's fiduciary duties.
ESPR: 16.74 (-1.01)

March 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Esperion Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Fri Mar 11, 8:30AM CST
Law Offices of Howard G. Smith reminds investors of the upcoming March 14, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period"

. Investors who suffered losses on their investment in Esperion securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights.
ESPR: 16.74 (-1.01)

Scott + Scott, LLP Notifies Investors That Monday, March 14, 2016 is Last Day to File Lead Plaintiff Papers in Esperion Therapeutics (ESPR) Securities Case
GlobeNewswire - Wed Mar 09, 7:45PM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 16.74 (-1.01)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Wed Mar 09, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company"

(Nasdaq: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period"

. Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 16.74 (-1.01)

Esperion Therapeutics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Tue Mar 08, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today announced Tim M. Mayleben, president and chief executive officer, will present at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 15, 2016 at 8:30 A.M. Eastern Time.
ESPR: 16.74 (-1.01)

Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit against Esperion Therapeutics, Inc.
BusinessWire - Tue Mar 08, 9:30AM CST
Glancy Prongay & Murray LLP ("GPM"

reminds investors that a class action complaint has been filed on behalf of a class of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period"

. Esperion investors have until March 14, 2016 to file a lead plaintiff motion. Investors are encouraged to contact GPM to discuss their legal rights.
ESPR: 16.74 (-1.01)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
PR Newswire - Tue Mar 08, 8:52AM CST
The following statement is being issued by Levi & Korsinsky, LLP:
ESPR: 16.74 (-1.01)

Scott + Scott, LLP Notifies Investors of Monday, March 14, 2016 Deadline in Esperion Therapeutics (ESPR) Securities Case
BusinessWire - Mon Mar 07, 10:39AM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 16.74 (-1.01)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Mon Mar 07, 9:01AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company"

(NASDAQ: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period"

. Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 16.74 (-1.01)

Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
GlobeNewswire - Mon Mar 07, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors there is a March 14, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against the Company related to the delayed approval of Esperion's leading cholesterol drug.
ESPR: 16.74 (-1.01)

SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc.
BusinessWire - Fri Mar 04, 8:15PM CST
Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) for potential violations of federal securities laws and breaches of the Esperion Board's fiduciary duties.
ESPR: 16.74 (-1.01)

SECURITIES NOTICE: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important March 14, 2016 Deadline in Class Action - ESPR
GlobeNewswire - Fri Mar 04, 2:30PM CST
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Esperion Therapeutics, Inc. securities (NASDAQ:ESPR) from August 18, 2015 through September 28, 2015, both dates inclusive (the "Class Period"

of the important March 14, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Esperion Therapeutics investors under the federal securities laws.
ESPR: 16.74 (-1.01)

INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Lawsuit Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
GlobeNewswire - Fri Mar 04, 11:04AM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ:ESPR) securities between August 18, 2015 and September 28, 2015.
ESPR: 16.74 (-1.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Clarivate's Upcoming Conference Presentation: What to Expect

Conference Time: Will Clarivate Deliver the Goods? Grab your calendars, folks. November 18 is when Clarivate Plc is stepping into the spotlight at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference. Their bigwigs, Matti Shem Tov, the CEO, and Michael Easton, the CFO, will be there to spill the beans. They’re set to take the mike...

Pharmacy Credentials Gain Importance in Delaware Law

Credentialing Takes Front Seat in Pharmacy World Well, hold onto your hats because the pharmacy profession is getting a major upgrade, particularly if you're an investor watching healthcare regulation. The American Association of Colleges of Pharmacy (AACP) has thrown its support behind professional credentialing for pharmacists, which is a big deal, trust me. Pharmacy...

Clarivate's IPOne Revolutionizes AI for IP Pros

A New Dawn for IP Intelligence: Clarivate's Strategic Move Seems like Clarivate's out to shake things up in the IP world. Today, they've announced that their coveted patent and litigation intelligence is now seamlessly integrated with AI workflows on Claude through IPOne. For those not neck-deep in patents and trademarks every day, let’s break it down. This means IP...

Sivers Expands Reach via WT Microelectronics Deal

Breaking Ground with Strategic Collaborations Sivers Semiconductors is flexing its muscles in the semiconductor industry with a new strategic distribution agreement. They announced a partnership with WT Microelectronics, a company that's no rookie in the electronics distribution scene. With WT's global network covering a hefty 43 countries and a clientele of over 25,000,...

Florida's Insurance Premiums: Why They Keep Skyrocketing

What’s Driving Up These Premiums? If you’ve ever felt like your wallet gets lighter every time you pay your insurance premium, welcome to the club. It seems like the cost of insurance in Florida is like a runaway train. But don't just blame the hurricanes. Yeah, they definitely play their part, but there’s a bigger picture lurking behind those price tags. Weather...

Ladera Resort Snags Prestigious Design Honor in 2027

Recognition for a Unique Architectural Gem What's embedded in the heartbeat of Ladera Resort in St. Lucia? A crazy blend of stunning architecture right smack between the Pitons that makes it like nowhere else on Earth. And guess what? Ladera just snagged the Best Design award for 2027 at the Condé Nast Johansens Awards for Excellence. Winning this honor isn’t about...

2026 Shaw Prize: Celebrating Science's Global Impact

Shaw Prize: A Global Stage for Science When it comes to celebrating scientific breakthroughs, the Shaw Prize is the gold standard. On November 10th, 2026, the event unfolded at the iconic Hong Kong Convention and Exhibition Centre, and it was all about honoring those pushing the envelope in science. It’s year 23 for the Shaw Prize, and this ceremony didn’t just hand...

Rain Agent Vaults: Revolutionizing Payments with AI

Innovative Payments with AI Power Alright, folks, Rain's gone and done something that's probably going to shake things up in the payments world—'cause they've given AI agents the ability to handle money like never before. We're not just talking about some run-of-the-mill integration here. This is a genuine game changer, promising to make agents as financially savvy as...

Iconic Brands Falter in New AI-Driven Consumer Landscape

Forget Recognition—It's All About Relevance Now Brand hearts are breaking, folks. That classic suite of household names just took a body blow from the Consequential Brand™ Test. Out of 73, a single champ emerged. Why? Because in the age where AI drives recommendations, it turns out recognizability ain't cutting it. This ain't your granddad’s customer loyalty game...